Provectus Biopharmaceuticals Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 2/6
Provectus Biopharmaceuticals has a total shareholder equity of $-7.5M and total debt of $3.0M, which brings its debt-to-equity ratio to -39.9%. Its total assets and total liabilities are $856.4K and $8.4M respectively.
Anahtar bilgiler
-39.9%
Borç/özkaynak oranı
US$3.00m
Borç
| Faiz karşılama oranı | n/a |
| Nakit | US$29.58k |
| Eşitlik | -US$7.51m |
| Toplam yükümlülükler | US$8.37m |
| Toplam varlıklar | US$856.43k |
Son finansal sağlık güncellemeleri
Güncelleme yok
Recent updates
Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: PVCT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Uzun Vadeli Yükümlülükler: PVCT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: PVCT has negative shareholder equity, which is a more serious situation than a high debt level.
Borcun Azaltılması: PVCT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Bilanço
Nakit Pist Analizi
Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.
İstikrarlı Nakit Pisti: PVCT has sufficient cash runway for 0 months based on last reported free cash flow, but has since raised additional capital.
Tahmini Nakit Akışı: PVCT is forecast to have sufficient cash runway for 0 months based on free cash flow estimates, but has since raised additional capital.